ADMA Biologics Q1 EPS Surges 73% to $0.19, Driven by ASCENIV Sales Growth
Summary
ADMA Biologics reported first-quarter 2026 results with diluted EPS jumping 72.7% to $0.19, and net income increasing 68.5% to $45.33 million, despite revenue remaining essentially flat at $114.49 million. This significant profitability growth was primarily driven by a 27.7% year-over-year increase in ASCENIV sales and operational efficiency gains, including FDA-approved yield enhancements for IVIG. This strong performance follows the recent FDA approval for the expansion of ASCENIV's label, indicating continued positive momentum for the product. The substantial improvement in earnings per share, despite flat revenue, signals strong margin expansion and effective cost management, which is a material positive for the company's financial outlook. Traders will be watching for continued operational efficiencies and the progress of the company's R&D pipeline.
At the time of this announcement, ADMA was trading at $7.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $23.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.